BCM
MYGN icon

BlueCrest Capital Management’s Myriad Genetics MYGN Stock Holding History

BlueCrest Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,200
Closed -$239K – 830
2019
Q1 		$239K Buy
+7,200
New +$219K 0.01% 841

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlueCrest Capital Management's MYGN Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 7,200 shares — an estimated $239K sold.

BlueCrest Capital Management first reported a position in MYGN in Q1 2019 and held it in 1 quarter. The position peaked at $239K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 7,200 Myriad Genetics shares in Q2 2019, an estimated $239K.
  • BlueCrest Capital Management first reported a position in Myriad Genetics in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Myriad Genetics position peaked at $239K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.